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Abstract
There are no prospective studies of aggressive non-Hodgkin lymphoma (NHL) treated with
CHOP in sub-Saharan Africa. We enrolled adults with aggressive NHL in Malawi between
June 2013 and May 2015. Chemotherapy and supportive care were standardized, and HIV
+ patients received antiretroviral therapy (ART). Thirty-seven of 58 patients (64%) were HIV
+. Median age was 47 years (IQR 39–56), and 35 (60%) were male. Thirty-five patients
(60%) had stage III/IV, 43 (74%) B symptoms, and 28 (48%) performance status2. B-cell
NHL predominated among HIV+ patients, and all T-cell NHL occurred among HIV- individu-
als. Thirty-one HIV+ patients (84%) were on ART for a median 9.9 months (IQR 1.1–31.7)
before NHL diagnosis, median CD4 was 121 cells/μL (IQR 61–244), and 43% had sup-
pressed HIV RNA. HIV+ patients received a similar number of CHOP cycles compared to
HIV- patients, but more frequently developed grade 3/4 neutropenia (84% vs 31%, p =
0.001), resulting in modestly lower cyclophosphamide and doxorubicin doses with longer
intervals between cycles. Twelve-month overall survival (OS) was 45% (95% CI 31–57%).
T-cell NHL (HR 3.90, p = 0.017), hemoglobin (HR 0.82 per g/dL, p = 0.017), albumin (HR
0.57 per g/dL, p = 0.019), and IPI (HR 2.02 per unit, p<0.001) were associated with mortal-
ity. HIV was not associated with mortality, and findings were similar among patients with dif-
fuse large B-cell lymphoma. Twenty-three deaths were from NHL (12 HIV+, 11 HIV-), and
12 from CHOP (9 HIV+, 3 HIV-). CHOP can be safe, effective, and feasible for aggressive
NHL in Malawi with and without HIV.
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Introduction
Non-Hodgkin lymphoma (NHL) is increasing in sub-Saharan Africa (SSA) [1–3], but clinical
features and outcomes are not well described. Reports have typically been retrospective, with
many excluded or untreated patients, and high loss to follow-up. Descriptions have also often
been before widespread availability of antiretroviral therapy (ART) for HIV.
NHL diagnosis in SSA is frequently based on fine needle aspirates (FNAs) without immuno-
histochemistry (IHC), flow cytometry, or molecular tools [4–6]. NHL is therefore often treated
as a single entity with CHOP being universally applied, given pathology limitations, restricted
chemotherapy formularies, and settings where more intense or complex regimens are impracti-
cal. Even in resource-rich countries, CHOP remains a standard backbone for many NHL sub-
types. The most important advance has been adding rituximab for CD20-positive NHL, which
is neither widely available nor well-studied in SSA.
Despite widespread use, there is no prospective description of first-line CHOP for adults
with NHL in SSA. In the only clinical trial for this population, CHOP salvage was administered
to 11 of 49 HIV-infected NHL patients who failed dose-modified oral chemotherapy in Kenya
and Uganda, during 2001–2005 when ART was not widely available [7]. In the modern era,
HIV-associated lymphoma patients in resource-rich settings can receive identical treatment
with equivalent outcomes to patients without HIV [8–13]. Retrospective descriptions from
Uganda and South Africa have also suggested CHOP can be effective, including for HIV-
infected individuals receiving ART [14, 15]. Given high infectious burden and limited cancer
infrastructure [16], a detailed prospective characterization of CHOP in SSA is important, and
was undertaken at a national teaching hospital in Malawi.
Methods
Patients and procedures
Kamuzu Central Hospital (KCH) is a cancer referral center for eight million people in Malawi,
a country which has 10% HIV prevalence, 67% ART coverage, and an annual gross domestic
product per capita of 314 US dollars [17, 18]. The KCH Lymphoma Study is an ongoing pro-
spective cohort approved by the University of North Carolina Institutional Review Board and
Malawi National Health Sciences Research Committee. Through active case finding across all
hospital departments and referring clinics, adults and children with newly diagnosed lym-
phoma were invited to participate after written informed consent. Informed consent forms and
consent procedures were approved by ethics committees in the US and Malawi. All diagnoses
were pathologically confirmed using tissue biopsies whenever possible, supported by IHC and
weekly telepathology consultation involving 2–4 US and Malawian pathologists [19]. Available
IHC stains included CD3, CD20, CD30, CD45, CD138, Ki-67, terminal deoxynucleotidyl
transferase (TDT), and latency-associated nuclear antigen (LANA). Other stains included
synaptophysin and AE1/AE3 to distinguish lymphomas from neuroendocrine or epithelial
tumors when morphology is equivocal. Definitively distinguishing Burkitt lymphoma (BL), dif-
fuse large B-cell lymphoma (DLBCL), and overlapping subtypes was difficult without cyto-
genetic and molecular tools. These subtypes were therefore grouped as aggressive B-cell NHL
and treated with CHOP, since infusional or more intensive regimens for BL or other NHL sub-
types were not feasible. All diagnostic specimens were shipped to the US for final classification,
although results were not available in time to guide frontline therapy.
Patients underwent comprehensive baseline evaluation including chest x-ray, abdominal
ultrasound, and bone marrow examination. Cerebrospinal fluid (CSF) cytology was recom-
mended for patients at high risk for leptomeningeal involvement (>1 extranodal site and
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elevated lactate dehydrogenase (LDH); involvement of bone marrow, testicular, epidural, ocu-
lar, breast, or paranasal sinus sites; or Ki67>90% suggesting BL or similarly aggressive B-cell
NHL). Patients received longitudinal follow-up with active tracing and transportation reim-
bursement to promote retention. Response was assessed using standardized criteria incorporat-
ing physical exam, chest x-ray, and abdominal ultrasound. For this report, we focused on
adults>18 years with newly diagnosed aggressive NHL enrolled between June 1, 2013 and
May 31, 2015.
There are no formal cancer treatment guidelines in Malawi. However, efforts to standardize
care have been ongoing. CHOP was administered every 21 days with cyclophoshamide 750
mg/m2 day 1, doxorubicin 50 mg/m2 day 1, vincristine 1.4 mg/m2 (maximum 2 mg) day 1, and
prednisone 60 mg/m2 (maximum 100 mg) days 1–5. Prior to each cycle, an absolute neutrophil
count (ANC) of 1.0x103/μL and platelet count of 100x103/μL were recommended. Intrathecal
methotrexate 12.5 mg and hydrocortisone 50 mg were recommended for patients at high risk
of leptomeningeal involvement as above. There is no radiotherapy in Malawi, and six cycles
were administered even for limited-stage disease. Patients who achieved partial response after
six cycles, and tolerated treatment without severe adverse events, could receive up to eight
cycles.
Blood counts and tests of kidney and liver function were performed on day 1 of each cycle
or interim visits as indicated. If blood counts prohibited chemotherapy, they were repeated one
week later and treatment proceeded if blood counts allowed. For a first episode of febrile neu-
tropenia or delayed blood count recovery, cyclophosphamide and doxorubicin were reduced
by 25%, and for a second episode doses were reduced by 50%, with subsequent dose escalation
at the treating physician’s discretion. Hematopoietic growth factors were not available. Patients
with age>70 years, performance status>2, and/or baseline cytopenias could receive prephase
prednisone and/or ‘mini-CHOP’ with 50% dose reductions of all cytotoxic agents for cycle 1,
and subsequent dose escalation at the treating physician’s discretion. Ciprofloxacin prophylaxis
was provided during days 8–15 of each cycle for patients with HIV, or patients without HIV
>60 years. Cotrimoxazole prophylaxis was continuously provided to all HIV-infected patients.
Fluconazole prophylaxis was provided to HIV-infected patients throughout chemotherapy
until resolution of neutropenia. Promethazine was provided for antiemesis. Consistent with
World Health Organization guidelines and anti-infective prophylaxis provided in US AIDS
Malignancy Consortium trials, we continued cotrimoxazole even in patients who developed
neutropenia due to demonstrated survival benefits for HIV-infected populations without can-
cer in SSA through its preventive effects against malaria, bacterial infection, and Pneumocystis.
All medicines were freely provided by the Ministry of Health, although drug shortages
occurred. External funding enabled a back-up supply to mitigate treatment interruptions.
Interval illnesses and complications were recorded prior to each cycle, and patients were
encouraged to return promptly for interim concerns. Toxicities were graded using National
Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. All
HIV-infected patients received ART concurrently with chemotherapy, typically with tenofovir-
lamivudine-efavirenz. Patients on ART with virologic failure were referred for adherence
counseling and consideration of second-line ART. We reduced vincristine by 50% in patients
receiving second-line ritonavir-based ART due to cytochrome P450 3A4 interactions.
Statistical analysis
Differences between HIV-infected and HIV–uninfected patients were assessed using Fisher’s
exact tests, one-way analysis of variance (ANOVA), and Kruskal-Wallis tests. Summative
curves for blood counts were derived by plotting median values over time across all patients
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within each group. Follow-up time was calculated from enrollment or CHOP initiation as spec-
ified, until death, loss to follow-up, or administrative censoring on August 31, 2015. Kaplan-
Meier curves were used to estimate overall survival (OS), and the log-rank test was used to
assess differences in survival between subgroups. Cox proportional hazards were used to esti-
mate unadjusted and adjusted hazard ratios for mortality. All analyses were conducted using
Stata version 12.1 (College Station, Texas, USA). A two-sided alpha value of 0.05 was consid-
ered statistically significant.
Results
Sixty-two patients18 years with newly diagnosed aggressive NHL presented to KCH between
June 1, 2013 and May 31, 2015, and 59 (95%) patients consented to participate. Of those who
presented for care, one patient could not give adequate informed consent, one patient elected
to receive treatment in Blantyre, and one patient declined study participation. Four additional
patients with aggressive NHL were identified through the pathology laboratory, but could not
be contacted despite repeated attempts to engage them in care. One additional enrolled patient
had follicular lymphoma with DLBCL transformation, leaving 58 enrolled adults with newly
diagnosed aggressive NHL without prior indolent lymphoma.
Baseline characteristics are shown in Table 1. Thirty-seven patients (64%) were HIV-
infected. Median age was 47 years [interquartile range (IQR) 39–56] and 35 (60%) were male.
Thirty-five patients (60%) had stage III/IV disease, B symptoms were present in 43 (74%), and
28 (48%) had performance status2. Aggressive B-cell NHL predominated among HIV-
infected patients, and all aggressive T-cell NHL occurred among HIV-negative individuals.
There was a tendency for HIV-negative patients to be older with bulkier disease and higher
hemoglobin than HIV-positive patients. HIV-negative patients also more frequently reported
symptom durations6 months. Thirty-one (84%) HIV-infected patients were on ART at lym-
phoma diagnosis for a median 9.9 months (IQR 1.1–31.7). Median CD4 at lymphoma diagno-
sis was 121 cells/μL (IQR 61–244), median HIV RNA was 3.5 log10copies/mL (IQR 1.3–4.8),
and 43% had suppressed HIV RNA<400 copies/mL.
Fifty patients (86%) initiated cytotoxic treatment, including 31/37 (84%) HIV-positive and
19/21 (90%) HIV-negative individuals. Median time between enrollment and cytotoxic treat-
ment initiation was 7 days (IQR 4–13). All eight patients (6 HIV+, 2 HIV-) not treated with
CHOP died before cytotoxic treatment could be initiated. Eleven of 50 patients (22%) treated
with CHOP began treatment with either prephase prednisone or dose-reduced mini-CHOP,
including 6/31 (19%) HIV-positive and 5/19 (26%) HIV-negative patients. Four (3 HIV+, 1
HIV-) received prephase prednisone followed by dose-reduced cytotoxic treatment with their
first cycle, three HIV-positive patients received prephase prednisone followed by full-dose
CHOP, and four HIV-negative patients initiated dose-reduced cytotoxic treatment without
prephase prednisone. Of eight patients who initiated dose-reduced cytotoxic treatment, four
subsequently proceeded to full-dose chemotherapy, with reasons for initial dose reduction
being impaired performance status (5), baseline cytopenias (2), and advanced age (1).
Achieved chemotherapy intensity and toxicities are shown in Table 2. HIV-infected patients
received a similar number of CHOP cycles compared to HIV-uninfected patients (median 6 vs
5, p = 0.59), but modestly lower cyclophosphamide and doxorubicin doses per cycle, with a
longer interval between cycles. Grade 3/4 neutropenia occurred in more HIV-infected than
HIV-uninfected patients (84% vs 31%, p = 0.001). Grade 3/4 anemia occurred in 24% of
patients overall without significant differences between HIV-positive and HIV-negative indi-
viduals, and only one grade 3/4 thrombocytopenia event occurred in the study population. Of
62 grade 3/4 neutropenia events, 54 (87%) were grade 3 and eight (13%) were grade 4 (Fig 1).
CHOP for Aggressive NHL in Malawi
PLOS ONE | DOI:10.1371/journal.pone.0150445 March 2, 2016 4 / 15
For both HIV-infected and HIV-uninfected patients, median ANC remained greater than
1x103/μL throughout treatment (Fig 2). Among those with HIV, median CD4 count increased to
146 cells/μL (IQR 98–265) and median HIV RNA decreased to 1.3 log10copies/mL (IQR 1.3–1.6)
at six months with 11 of 13 patients (85%) having suppressed HIV RNA<400 copies/mL.
Table 1. Baseline characteristics for adults with aggressive non-Hodgkin lymphoma in Lilongwe, Malawi, June 2013 to May 2015.
HIV-positive (n = 37) HIV-negative (n = 21) P
Age, years, median (IQR) 47.0 (38.1–50.2) 54.6 (43.9–61.8) 0.044
Male, n (%) 22 (59.5%) 13 (61.9%) 1.00
Body mass index, kg/m2, median (IQR) 20.8 (18.9–24.3) 20.3 (17.7–22.1) 0.39
Histologic diagnosis, n (%) 34 (91.9%) 19 (90.5%) 1.00
Malawi diagnosisa 0.014
Aggressive B-cell lymphoma 37 17
Aggressive T-cell lymphoma — 4
United States diagnosisb 0.19
Diffuse large B-cell lymphoma 26 13
Burkitt lymphoma 2 1
Plasmablastic lymphoma 2 1
High-grade B-cell lymphoma NOS 2 1
Extranodal NK/T-cell lymphoma — 3
ALK-negative anaplastic large-cell lymphoma — 1
Symptom duration 6 months, n (%) 3/36 (8.3%) 7/20 (35.0%) 0.025
B symptoms, n (%) 26 (70.3%) 17 (81.0%) 0.54
Largest lymph node mass, cm, median (IQR) 10 (6–12) 11 (9–17) 0.056
Performance status 2, n (%) 16 (43.2%) 12 (57.1%) 0.41
Stage III/IV, n (%) 24 (64.9%) 11 (52.4%) 0.41
International prognostic index 3, n (%) 12 (32.4%) 8 (38.1%) 0.78
White blood cells, 103/μL, median (IQR) 5.7 (4.2–7.6) 5.6 (4.4–8.9) 0.59
Absolute neutrophil count, 103/μL, median (IQR) 2.6 (1.8–4.1) 2.9 (2.5–5.7) 0.14
Hemoglobin, g/dL, median (IQR) 11.0 (9.2–12.4) 12.4 (11.0–13.3) 0.038
Platelets, 103/μL, median (IQR) 263 (184–402) 290 (232–425) 0.40
Albumin, g/dL, median (IQR) 3.4 (2.9–4.0) 3.2 (3.0–3.8) 0.73
Lactate dehydrogenase, IU/L, median (IQR)c 602 (338–1,294) 441 (283–571) 0.11
Abnormal lactate dehydrogenase, n (%) 33 (89.2%) 17 (81.0%) 0.44
Bone marrow involvement, n (%) 5/27 (18.5%) 0/17 (0.0%) 0.14
2 extranodal sites, n (%) 6 (16.2%) 4 (19.0%) 1.00
Hepatitis B surface antigen positive, n (%) 6/36 (16.7%) 1/19 (5.3%) 0.40
ART at enrollment, n (%) 31 (83.8%) — —
ART duration at enrollment, months, median (IQR) 9.9 (1.1–31.7)
CD4 count, cells/μL, median (IQR) 121 (61–244) — —
HIV RNA, log10copies/mL, median (IQR) 3.5 (1.3–4.8) — —
HIV RNA <400 copies/mL, n (%) 16 (43.2%) — —
IQR = interquartile range. NOS = not otherwise specified. ART = antiretroviral therapy.
aMalawi diagnoses reflect limited immunohistochemistry staining and weekly consensus telepathology discussion by United States and Malawi
pathologists.
bUnited States diagnoses reflect delayed review of 52 cases with additional immunohistochemistry, fluorescence in situ hybridization, and molecular
studies in Chapel Hill.
cLaboratory upper limit of normal is 250 IU/L.
doi:10.1371/journal.pone.0150445.t001
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Eighteen grade 3/4 non-hematologic toxicities occurred, including nine grade 3 diarrhea/
dehydration, two grade 3 abdominal pain, two grade 3 skin infection, one grade 4 cerebral
edema, one grade 4 renal failure, one grade 3 small bowel obstruction, one grade 3 hepatitis,
and one grade 3 sepsis without neutropenia. Cerebral edema occurred in a patient with sys-
temic and central nervous system NHL progression. Obstructive renal failure, abdominal pain,
and small bowel obstruction occurred in patients with abdominal NHL progressing on CHOP.
Both grade 3 skin infections occurred when large masses ulcerated during CHOP and became
superinfected. Of 38 CHOP cycles delayed at least seven days (31 HIV+, 7 HIV-), 31 were due
to delayed ANC recovery, three for personal or transportation issues, three for clinic schedul-
ing, and one for pharmacy stock-out.
As of August 31, 2015, vital status was known for all 58 patients with no loss to follow-up
after a median 14.9 months among patients still alive (IQR 7.8–24.4). Among 49 patients who
initiated first-line CHOP and completed treatment or died before the censoring date, 22 (45%)
achieved a complete response (CR) after a median 2 CHOP cycles (IQR 1–3) including 15 of
30 (50%) HIV-infected patients and 7 of 19 (37%) HIV-uninfected patients (p = 0.40). One
HIV-infected patient was still receiving first-line CHOP and had achieved CR after four cycles.
Kaplan-Meier OS curves are shown in Fig 3, and OS estimates are shown in Table 3 for all
enrolled patients and patients who initiated cytotoxic treatment. Kaplan-Meier 12-month OS
Table 2. Treatment course and toxicities during CHOP chemotherapy in Lilongwe, Malawi.
HIV-positive (n = 31) HIV-negative (n = 19) P
Total chemotherapy cycles 150 88 —
Cycles per patient, median (IQR)a 6 (4–6) 5 (3–6) 0.59
Days between cycles, median (IQR) 21 (21–27) 21 (20–22) 0.0053
Cycles delayed 7 days, n (%)b 32/119 (26.9%) 8/69 (11.6%) 0.016
Cyclophosphamide dose per cycle, mg/m2, median (IQR)c 693.0 (555.6–734.8) 721.4 (576.9–750.0) 0.015
Doxorubicin dose per cycle, mg/m2, median (IQR)d 48.0 (37.6–49.9) 49.4 (39.3–50.0) 0.042
Received <6 cycles, n (%)a 14/30 (46.7%) 11/19 (57.9%) 0.56
Death 7 6
Progression 1 2
Toxicity 5 1
Social 1 2
Grade 3/4 neutropeniae
Cycles, n (%) 49/140 (35.0%) 13/83 (15.7%) 0.002
Patients, n (%) 21/25 (84.0%) 5/16 (31.2%) 0.001
Grade 3/4 anemiae
Cycles, n (%) 13/140 (8.9%) 6/83 (7.2%) 0.80
Patients, n (%) 7/25 (28.0%) 3/16 (18.8%) 0.71
Grade 3/4 non-hematologic toxicitye
Cycles, n (%) 6/140 (4.3%) 12/83 (14.5%) 0.010
Patients, n (%) 6/25 (24.0%) 8/17 (47.1%) 0.18
IQR = interquartile range.
aIncludes 49 patients (30 HIV+, 19 HIV-) who completed first-line CHOP or died as of August 31, 2015.
bExcudes first treatment cycles.
cExcludes 9 missed cyclophosphamide doses due to stock-out (6 HIV-, 3 HIV+).
dExcludes 6 missed doxorubicin doses due to stock-out (4 HIV-, 2 HIV+).
eToxicity assessment includes patients and cycles with subsequent follow-up visits making them evaluable for interim toxicity; deaths occurring out of
hospital are separately adjudicated (S1 Table) without evaluation for non-fatal interim toxicity.
doi:10.1371/journal.pone.0150445.t002
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was 45% [95% confidence interval (CI) 31–57%] for the cohort overall. OS was similar for
HIV-infected and HIV-uninfected patients, better for those with international prognostic
index (IPI)<3, and better for those with aggressive B-cell NHL than T-cell NHL. Among 50
patients who initiated cytotoxic treatment, estimated 12-month OS was 52% (95% CI 37–65%).
For cases confirmed as DLBCL in the US, 12-month OS was 51% (95% CI 34–65%) for all
patients (n = 39) and 56% (95% CI 38–71%) for those who initiated cytotoxic treatment
(n = 35), with similar survival by HIV status and better survival for those with IPI<3.
Risk factors for mortality are shown in Table 4. In unadjusted analyses, T-cell NHL (HR
3.90, p = 0.017), hemoglobin (HR 0.82 per g/dL increase, p = 0.017), albumin (HR 0.57 per g/
dL increase, p = 0.019), and IPI (HR 2.02 per unit increase, p<0.001) were associated with
mortality. When individual IPI elements were examined, performance status (HR 1.91 per unit
increase, p<0.001), LDH (HR 1.04 per 100 IU/L increase, p = 0.002), number of extranodal
sites (HR 1.66 per site, p = 0.006), and stage III/IV (HR 2.33, p = 0.025) were associated with
mortality. In adjusted analyses, only IPI was associated with mortality (HR 1.77 per unit
increase, p = 0.005). HIV was not associated with mortality, and findings were similar among
patients confirmed as DLBCL in the US.
Fig 1. Neutropenia during CHOP chemotherapy in Lilongwe, Malawi.
doi:10.1371/journal.pone.0150445.g001
Fig 2. Peripheral blood counts with interquartile ranges during CHOP chemotherapy in Lilongwe, Malawi.
doi:10.1371/journal.pone.0150445.g002
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There is no national death registration in Malawi. Although patients are encouraged to
return promptly for interim illnesses, deaths often occur at home or in facilities with limited
diagnostic resources. Central adjudication of 35 deaths was undertaken to attribute cause (S1
Table). Twenty-three were attributed to lymphoma (12 HIV+, 11 HIV-), and 12 to CHOP
treatment (9 HIV+, 3 HIV-). As shown, most treatment-related deaths occurred in patients
with very adverse NHL characteristics.
Discussion
This is the first prospective description of adults with aggressive NHL receiving frontline
CHOP in SSA.
For HIV-infected NHL patients in Lilongwe, 50% OS at 12 months, and 59% among
patients initiating CHOP, are among the best survival estimates reported at this time point
from SSA [7, 14, 15]. This is a testament to the Malawi HIV program, which provides ART to
67% of HIV-infected individuals who require treatment [17]. Although 84% of our patients
were on ART, median ART duration at lymphoma diagnosis was only 9.9 months with median
Fig 3. Overall survival for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi. (A) Overall cohort with 95% confidence intervals. (B) Aggressive B-
cell non-Hodgkin lymphoma (ABNHL) versus aggressive T-cell non-Hodgkin lymphoma (ATNHL). (C) Stratified by HIV status. (D) Stratified by international
prognostic index (IPI). (E) Diffuse large B-cell lymphoma (DLBCL) stratified by HIV status. (F) DBLCL stratified by IPI.
doi:10.1371/journal.pone.0150445.g003
Table 3. Overall survival estimates for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.
N 12-month OS (%) 95% CI 24-month OS (%) 95% CI
Enrolleda
All 58 44.7 31.2–57.3 34.0 20.9–47.6
HIV+ 37 49.7 32.4–64.9 37.4 20.5–54.3
HIV- 21 35.6 15.8–56.1 28.5 10.4–49.9
IPI<3 38 61.5 43.6–75.2 45.1 26.8–61.9
IPI> = 3 20 13.3 2.6–32.7 13.3 2.7–32.7
DLBCL 39 50.6 33.9–65.0 40.8 24.8–56.3
HIV+ 26 52.8 31.9–69.9 43.2 23.2–61.7
HIV- 13 46.2 19.2–69.6 36.9 12.5–62.0
IPI<3 27 65.8 44.5–80.6 51.3 29.9–69.2
IPI> = 3 12 16.7 2.6–41.3 16.7 2.6–41.3
Treatedb
All 50 51.9 36.8–65.1 39.3 24.1–54.1
HIV+ 31 59.4 39.3–74.7 44.3 24.2–62.7
HIV- 19 39.4 17.5–60.7 31.5 11.4–54.1
IPI<3 35 66.8 47.8–80.1 48.9 28.7–66.0
IPI> = 3 15 17.8 3.4–41.4 17.8 3.4–41.4
DLBCL 35 56.3 38.2–71.0 45.2 27.4–61.4
HIV+ 23 59.6 36.5–76.7 48.2 25.6–67.6
HIV- 12 50.0 20.8–73.6 40.0 13.5–65.7
IPI<3 24 74.1 51.0–87.5 57.1 32.9–75.4
IPI> = 3 11 18.2 2.8–44.2 18.2 2.8–44.2
OS = overall survival. CI = confidence interval. IPI = International Prognostic Index.
aSurvival measured from enrollment.
bSurvival measured from cytotoxic treatment initiation.
doi:10.1371/journal.pone.0150445.t003
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CD4 count 121 cells/μL, highlighting a need for continued scale-up and earlier ART applica-
tion. ART coverage, immune status, and HIV control in our cohort are comparable to similar
routine-care populations in the US [20]. Although HIV-infected NHL patients with excellent
outcomes similar to HIV-negative individuals have been repeatedly described in clinical trials
from resource-rich settings (8–13), our prior work in a multicenter routine-care cohort in the
Table 4. Risk factors for mortality among aggressive non-Hodgkin lymphoma patients in Lilongwe, Malawi.
Unadjusted hazard
ratio
95% confidence
interval
P Adjusted hazard
ratioa
95% confidence
interval
P
All (n = 58)
HIV infection 0.82 0.41–1.61 0.56 0.90 0.39–2.07 0.81
T-cell non-Hodgkin lymphoma 3.90 1.28–11.91 0.017 3.06 0.74–12.72 0.12
Female sex 0.80 0.40–1.61 0.53 0.57 0.26–1.24 0.16
Hemoglobin, per g/dL 0.82 0.70–0.97 0.017 0.92 0.74–1.14 0.44
Albumin, per g/dL 0.57 0.36–0.91 0.019 1.07 0.53–2.17 0.85
Body mass index, per kg/m2 0.95 0.86–1.05 0.29 1.00 0.90–1.11 0.98
International prognostic index, per
unit
2.02 1.45–2.82 <0.001 1.77 1.18–2.64 0.005
Age, per year 1.00 0.97–1.02 0.85 — — —
Age >60 years 0.75 0.33–1.73 0.50 — — —
Performance status, per unit 1.91 1.45–2.52 <0.001 — — —
Performance status 2 4.96 2.34–10.50 <0.001 — — —
Stage III/IV 2.32 1.11–4.85 0.025 — — —
Lactate dehydrogenase, per 100
IU/L
1.04 1.01–1.07 0.002 — — —
Abnormal lactate
dehydrogenase
1.81 0.63–5.16 0.27 — — —
Extranodal sites, per site 1.66 1.16–2.38 0.006 — — —
2 extranodal sites 2.59 1.13–5.96 0.025 — — —
DLBCL only (n = 39)
HIV infection 0.86 0.36–2.05 0.73 1.37 0.50–3.76 0.54
Female sex 1.05 0.44–2.51 0.91 1.99 0.67–5.91 0.21
Hemoglobin, per g/dL 0.89 0.71–1.12 0.32 1.07 0.82–1.41 0.60
Albumin, per g/dL 0.64 0.33–1.23 0.18 0.89 0.35–2.26 0.80
Body mass index, per kg/m2 0.97 0.87–1.09 0.65 1.09 0.95–1.25 0.17
International prognostic index, per
unit
2.37 1.49–3.77 <0.001 2.94 1.49–5.83 0.002
Age, per year 1.01 0.98–1.04 0.62 — — —
Age >60 years 0.79 0.27–2.33 0.66 — — —
Performance status, per unit 1.81 1.27–2.57 0.001 — — —
Performance status 2 6.11 2.39–15.59 <0.001 — — —
Stage III/IV 2.54 0.94–6.91 0.067 — — —
Lactate dehydrogenase, per 100
IU/L
1.13 1.06–1.21 <0.001 — — —
Abnormal lactate
dehydrogenase
2.44 0.57–10.54 0.23 — — —
Extranodal sites, per site 1.54 0.99–2.41 0.057 — — —
2 extranodal sites 3.47 1.13–10.62 0.030 — — —
DLBCL = diffuse large B-cell lymphoma.
aAdjusted for all variables for which hazard ratios are shown.
doi:10.1371/journal.pone.0150445.t004
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US demonstrated a CD4 count of 123 cells/μL and HIV RNA suppression in only 28% at
DLBCL diagnosis, among 201 patients with HIV-associated DLBCL receiving care in the ART
era between 1996 and 2010, with 56% two-year overall survival (20). These characteristics are
fairly similar to our Malawi cohort.
Despite increased treatment-related toxicity and deaths in the Malawi HIV-infected NHL
population, our experience attests to the potential safety, effectiveness, and feasibility of CHOP
in the current era, when accompanied by standardized monitoring, dose adjustment, support-
ive care, and ART, as also suggested by other studies [14, 15]. Most deaths among HIV-positive
patients were from NHL rather than treatment. Treatment-related mortality occurred primar-
ily in patients with very adverse NHL characteristics, and might be reduced with supportive
care refinements. In particular, hematopoietic growth factors, which exist as generic biosimilars
although even these are still too expensive for the Malawi public sector, could substantially mit-
igate toxicity since neutropenia was by far the most frequent adverse event. To our knowledge,
the only alternative regimen to CHOP for HIV-associated NHL in SSA with published data is
the dose-modified oral chemotherapy regimen (lomustine, etoposide, cyclophosphamide, pro-
carbazine). In 49 patients with HIV-associated NHL in Kenya and Uganda before ART was
widely available, this treatment resulted in median survival of 12.3 months and 33% five-year
overall survival. Of note, the trial had major exclusions with respect to performance status,
anticipated life expectancy, blood counts, and liver/kidney function, resulting in only 33% of
screened HIV-associated NHL patients being enrolled, making it difficult to draw direct com-
parisons with our unselected patient population in Lilongwe.
HIV-negative lymphoma patients in Malawi are very ill with advanced, bulky disease and
poor outcomes. More than three-quarters of deaths were attributed to NHL rather than treat-
ment in the HIV-uninfected group. Massive HIV-related investments have occurred in SSA in
recent years, which has created a strong network of HIV clinics throughout Malawi. No such
primary care network exists for HIV-negative individuals, who consequently suffer from
delayed referral and diagnosis. Delays were multifactorial and typically occurred before presen-
tation to our center, as we made concerted efforts to expedite diagnostic work-ups and treat-
ment initiation once patients entered our care. Absent radiotherapy in Malawi also contributes
to poor outcomes, particularly for HIV-negative patients, who tend to present with localized,
bulky disease, as radiotherapy improves outcomes for bulky NHL compared with chemother-
apy alone [21, 22]. Occurrence of particularly aggressive lymphoma subtypes including T-cell
NHL among HIV-uninfected patients also resulted in poor survival. Equivalent outcomes for
HIV-positive NHL patients in Malawi are consistent with Uganda data suggesting HIV was
not associated with worse survival for NHL [23].
Study strengths include prospective, longitudinal follow-up of NHL cases confirmed using
real-time consensus telepathology, supported by IHC and multiple US and Malawi pathologists.
This is notable given that diagnostic pathology was unavailable in Lilongwe before July 2011, and
only 18% of cases in the Malawi national cancer registry were pathologically confirmed in the
most recent report [24]. Subsequent secondary review was also performed by US hematopatholo-
gists. Patients underwent detailed and systematic clinical characterization, and those with HIV
received concurrent ART in a mature national program. Patients were actively followed, and no
enrolled patient has been lost to date with a median follow-up of 14.9 months among patients still
alive. Median follow-up in studies from the region ranges from 3.5 to 8.2 months [7, 14, 15], and
survival can be significantly overestimated in SSA when patients are lost to follow-up [25, 26]. We
also made efforts to standardize chemotherapy, including strategies aimed at frail patients to mini-
mize induction deaths. Our study lacked major exclusions and achieved 95% enrollment among
NHL patients presenting for care, of whom 86% initiated cytotoxic therapy. Other NHL studies
from SSA have reported 26–67% of patients being excluded or untreated [7, 14, 15].
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Limitations include referral bias intrinsic to the Malawi health system, given centralization
of cancer services in Lilongwe and Blantyre, the two largest cities. Many NHL patients may die
before presenting to a national teaching hospital. Similarly, patients with asymptomatic lymph-
adenopathy may not travel to central hospitals, leading to underrepresentation of less aggres-
sive disease. Another limitation is absent death certification in Malawi, leading us to attribute
causation through centralized review.
Our results suggest a global strategy to improve outcomes for NHL patients is possible. HIV
investments should be leveraged for populations with and without HIV. Community and
health care worker education can facilitate earlier referral and diagnosis. Supportive care
should be standardized and refined, informed by better identification of complications during
treatment, with resource-appropriate incorporation of hematopoietic growth factors. Protocol-
guided chemotherapy with defined strategies for monitoring and dose adjustment should be
adopted. Ensuring continuous chemotherapy supply and incorporating newer agents to pro-
vide better first-line and salvage treatment options is also important. We believe a dedicated
study of rituximab in SSA is an urgent priority to demonstrate safety and efficacy in severely
resource-constrained settings like Malawi. This is important in light of rituximab’s impending
patent expiration, successful use of an existing biosimilar, and increasing experience with sub-
cutaneous administration which enhances feasibility for SSA [27, 28]. Non-radiotherapy strate-
gies for localized bulky NHL also deserve investigation given radiotherapy scarcity in SSA [29].
Finally, biologic insights can guide treatment, and we have begun molecular profiling and viro-
logic studies of Malawi NHL specimens to be reported subsequently.
In conclusion, CHOP can be safe, effective, and feasible for aggressive NHL patients with
and without HIV in resource-limited settings in SSA. Among HIV-positive patients, ART use,
CD4 count, and HIV RNA at lymphoma diagnosis are comparable to contemporary HIV-asso-
ciated NHL cohorts in the US, as are outcomes for patients treated with CHOP. Multifaceted
approaches are needed to improve survival, and these should target both HIV-infected and
HIV-uninfected individuals.
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